Andrew Godkin

7.4k total citations · 1 hit paper
95 papers, 5.2k citations indexed

About

Andrew Godkin is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Andrew Godkin has authored 95 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Immunology, 30 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Andrew Godkin's work include Immune Cell Function and Interaction (50 papers), T-cell and B-cell Immunology (45 papers) and Immunotherapy and Immune Responses (36 papers). Andrew Godkin is often cited by papers focused on Immune Cell Function and Interaction (50 papers), T-cell and B-cell Immunology (45 papers) and Immunotherapy and Immune Responses (36 papers). Andrew Godkin collaborates with scholars based in United Kingdom, Canada and United States. Andrew Godkin's co-authors include Awen Gallimore, Adrian V. S. Hill, Emma Jones, Tim Elliott, Derek P. Jewell, Pilar Dégano, Robert P. Anderson, Rolf M. Zinkernagel, Alain C. Tissot and Andreas Plückthun and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Andrew Godkin

95 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes

1998 656 citations Awen Gallimore, Andrew Godkin et al. profile →

Peers

Countries citing papers authored by Andrew Godkin

Since Specialization

Citations

This map shows the geographic impact of Andrew Godkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Godkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Godkin more than expected).

Fields of papers citing papers by Andrew Godkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Godkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Godkin. The network helps show where Andrew Godkin may publish in the future.

Co-authorship network of co-authors of Andrew Godkin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Godkin. A scholar is included among the top collaborators of Andrew Godkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Godkin. Andrew Godkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019 2023 ·World Journal of Hepatology ·Tom Pembroke, Gareth John, (unknown), (unknown), (unknown), (unknown), Marek Czajkowski, Andrew Godkin, Jane E. Salmon, Andrew D. Yeoman	4
2	Three-dimensional Imaging Reveals Immune-driven Tumor-associated High Endothelial Venules as a Key Correlate of Tumor Rejection Following Depletion of Regulatory T Cells 2022 ·Cancer Research Communications ·(unknown), Jun Abe, Emma Jones, (unknown), Kathryn Smart, Sarah N. Lauder, Michelle Somerville, Carl F. Ware, Andrew Godkin, Jens V. Stein, Gib Bogle, Awen Gallimore	3
3	Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity 2021 ·PubMed ·Stephanie Burnell, (unknown), Bruce J. MacLachlan, (unknown), Awen Gallimore, Andrew Godkin	42
4	Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection 2020 ·Cancer Immunology Research ·(unknown), Alexander Greenshields‐Watson, Emma Jones, Kathryn Smart, Sarah N. Lauder, Michelle Somerville, (unknown), Howard Kendrick, James P. Hindley, Rhiannon French, Matthew J. Smalley, William J. Watkins, Robert Andrews, Andrew Godkin, Awen Gallimore	22
5	Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells 2020 ·Clinical Cancer Research ·Martin Scurr, (unknown), (unknown), Michelle Somerville, Yuan Chen, Sarah L. Hulin-Curtis, Stephanie Burnell, James A. Davies, Michael Davies, Rachel Hargest, Simon Phillips, Adam Christian, Kevin E. Ashelford, Robert Andrews, Alan L. Parker, Richard J. Stanton, Awen Gallimore, Andrew Godkin	3
6	Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion 2020 ·Cancer Immunology Immunotherapy ·(unknown), Sarah N. Lauder, Kathryn Smart, Anja Bloom, Jake Scott, Emma Jones, Michelle Somerville, Molly Browne, (unknown), Andrew Godkin, Ann Ager, Awen Gallimore	12
7	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer 2017 ·Clinical Cancer Research ·Martin Scurr, Tom Pembroke, Anja Bloom, David C. S. Roberts, Amanda Thomson, Kathryn Smart, Hayley Bridgeman, Richard Adams, A. Brewster, Robert H. Jones, Sarah Gwynne, Daniel G. Blount, Richard Harrop, Robert K. Hills, Awen Gallimore, Andrew Godkin	119
8	Treg Depletion Licenses T Cell–Driven HEV Neogenesis and Promotes Tumor Destruction 2017 ·Cancer Immunology Research ·Emily J. Colbeck, Emma Jones, James P. Hindley, Kathryn Smart, Ralph Schulz, Molly Browne, (unknown), Anwen S. Williams, Lee Parry, Andrew Godkin, Carl F. Ware, Ann Ager, Awen Gallimore	94
9	Escalating Regulation of 5T4-Specific IFN-γ+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy 2013 ·Cancer Immunology Research ·Martin Scurr, Anja Bloom, Tom Pembroke, Rohit Srinivasan, (unknown), Kathryn Smart, Hayley Bridgeman, (unknown), Rachel Hargest, Simon Phillips, Adam Christian, (unknown), Awen Gallimore, Andrew Godkin	15
10	The paradox of NKp46 ⁺ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment 2013 ·Gut ·Tom Pembroke, Adam Christian, Emma Jones, Robert K. Hills, Eddie C. Y. Wang, Awen Gallimore, Andrew Godkin	50
11	T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion 2012 ·Cancer Research ·James P. Hindley, Emma Jones, Kathryn Smart, Hayley Bridgeman, Sarah N. Lauder, Beatrice Ondondo, (unknown), Kristin Ladell, Katherine K. Wynn, David R. Withers, David A. Price, Ann Ager, Andrew Godkin, Awen Gallimore	96
12	Avidity of influenza‐specific memory CD8⁺T‐cell populations decays over time compromising antiviral immunity 2012 ·European Journal of Immunology ·Ian R. Humphreys, Mathew Clement, Morgan Marsden, Kristin Ladell, James E. McLaren, Kathryn Smart, James P. Hindley, Hayley Bridgeman, Hugo A. van den Berg, David A. Price, Ann Ager, Linda Wooldridge, Andrew Godkin, Awen Gallimore	3
13	Rapid early innate control of hepatitis C virus during IFN‐α treatment compromises adaptive CD4⁺T‐cell immunity 2012 ·European Journal of Immunology ·Tom Pembroke, Ian Rees, Kathleen Gallagher, Emma Jones, (unknown), (unknown), Andrew N. Freedman, Ceri A. Fielding, Ian R. Humphreys, Eddie C. Y. Wang, Awen Gallimore, Andrew Godkin	10
14	Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors 2010 ·Cancer Research ·James P. Hindley, Cristina Ferreira, Emma Jones, Sarah N. Lauder, Kristin Ladell, Katherine K. Wynn, Gareth Betts, Yogesh Singh, David A. Price, Andrew Godkin, Julian Dyson, Awen Gallimore	97
15	Novel role of regulatory T cells in limiting early neutrophil responses in skin 2010 ·Immunology ·Hannah Richards, Anwen S. Williams, Emma Jones, James P. Hindley, Andrew Godkin, Anna Katharina Simon, Awen Gallimore	44
16	CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy? 2009 ·The Journal of Immunology ·Baalasubramanian Sivasankar, M. Paula Longhi, Kathleen Gallagher, Gareth Betts, B. Paul Morgan, Andrew Godkin, Awen Gallimore	44
17	Type I Interferon (IFNα) Acts Directly on Human Memory CD4+ T Cells Altering Their Response to Antigen 2009 ·The Journal of Immunology ·Kathleen Gallagher, Sarah N. Lauder, Ian Rees, Awen Gallimore, Andrew Godkin	35
18	Expansion of hepatitis C–specific CD4+CD25+ regulatory T cells after viral clearance: A mechanism to limit collateral damage? 2008 ·Journal of Allergy and Clinical Immunology ·Andrew Godkin, Wan‐Fai Ng, Kathleen Gallagher, Gareth Betts, Howard C. Thomas, Robert I. Lechler	16
19	The impact of regulatory T cells on carcinogen-induced sarcogenesis 2007 ·British Journal of Cancer ·Gareth Betts, Jason P. Twohig, Maries van den Broek, Sophie Sierro, Andrew Godkin, Awen Gallimore	56
20	Regulatory T cells inhibit Fas ligand‐induced innate and adaptive tumour immunity 2007 ·European Journal of Immunology ·Anna Katharina Simon, Emma Jones, Hannah Richards, (unknown), Gareth Betts, Andrew Godkin, Gavin Screaton, Awen Gallimore	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact